Bannerman Wealth Management Group LLC Invests $327,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bannerman Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,391 shares of the biopharmaceutical company's stock, valued at approximately $327,000. Alnylam Pharmaceuticals makes up approximately 0.3% of Bannerman Wealth Management Group LLC's portfolio, making the stock its 23rd biggest holding.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $243,000. Exchange Traded Concepts LLC grew its stake in shares of Alnylam Pharmaceuticals by 7.4% during the 4th quarter. Exchange Traded Concepts LLC now owns 3,833 shares of the biopharmaceutical company's stock valued at $902,000 after acquiring an additional 265 shares during the period. Blue Trust Inc. grew its stake in shares of Alnylam Pharmaceuticals by 192.2% during the 4th quarter. Blue Trust Inc. now owns 1,350 shares of the biopharmaceutical company's stock valued at $318,000 after acquiring an additional 888 shares during the period. SteelPeak Wealth LLC grew its stake in shares of Alnylam Pharmaceuticals by 40.6% during the 4th quarter. SteelPeak Wealth LLC now owns 3,480 shares of the biopharmaceutical company's stock valued at $819,000 after acquiring an additional 1,005 shares during the period. Finally, R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $33,000. Institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price target on the stock. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $11.69 during trading hours on Friday, hitting $304.59. 3,116,157 shares of the stock traded hands, compared to its average volume of 929,720. The firm's 50 day moving average price is $259.91 and its 200-day moving average price is $254.83. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $39.71 billion, a price-to-earnings ratio of -140.36 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 1 year low of $147.25 and a 1 year high of $306.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the prior year, the company posted ($0.16) EPS. The firm's revenue was up 20.2% compared to the same quarter last year. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.